HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PPI Products Must Warn Of Possible Increased Fracture Risk - FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA requires manufacturers to warn consumers that using proton pump inhibitors could increase the risk of some fractures, even though current research does not establish a causal link between the drug and fracture risk

You may also be interested in...

In Brief

FDA reverses on OTC PPI fracture risk

In Brief

C&D may cover costs by raising prices

Study Questions “Liberal” Proton Pump Inhibitor Use

A Canadian study supporting a link between proton pump inhibitors and osteoporosis-related fractures could lead to questions about OTC access to PPIs and shows a need to educate consumers regarding individual fracture risk, the authors say

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts